Get the Stockscreener App
79.90
0.11%
-0.09
After Hours:
79.93
0.03
+0.04%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $79.90, with a volume of 2.82M.
It is down -0.11% in the last 24 hours and up +8.00% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$79.99
Open:
$79.59
24h Volume:
2.82M
Relative Volume:
0.64
Market Cap:
$247.80B
Revenue:
$56.53B
Net Income/Loss:
$8.32B
P/E Ratio:
29.82
EPS:
2.6798
Net Cash Flow:
$8.49B
1W Performance:
-1.32%
1M Performance:
+8.00%
6M Performance:
+5.62%
1Y Performance:
-8.48%
1-Day Range:
$79.37
$80.09
1-Week Range:
$79.35
$81.52
52-Week Range:
$61.24
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
79.90 | 248.01B | 56.53B | 8.32B | 8.49B | 2.6798 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca Announces Current Share Capital and Voting Rights - TipRanks
Published on: 2025-09-01 16:47:49 - خودرو بانک
AstraZeneca’s baxdrostat shows promise in Phase III hypertension trial - Clinical Trials Arena
What candlestick patterns are forming on AstraZeneca PLC Depositary ReceiptPortfolio Return Report & High Yield Equity Trading Tips - Newser
After this weekend’s news, is it time to look again at the AstraZeneca share price? - MSN
Signal strength of AstraZeneca PLC Depositary Receipt stock in tech scannersEarnings Recap Report & Long-Term Safe Investment Ideas - Newser
Multi asset correlation models including AstraZeneca PLC Depositary ReceiptPortfolio Performance Report & Reliable Entry Point Trade Alerts - Newser
How to recover losses in AstraZeneca PLC Depositary Receipt stockJuly 2025 Reactions & Community Supported Trade Ideas - Newser
What momentum shifts mean for AstraZeneca PLC Depositary ReceiptJuly 2025 Breakouts & AI Powered Market Trend Analysis - Newser
Real time scanner hits for AstraZeneca PLC Depositary Receipt explainedForecast Cut & High Win Rate Trade Alerts - Newser
What institutional flow reveals about AstraZeneca PLC Depositary ReceiptEarnings Performance Report & AI Driven Stock Movement Reports - Newser
AstraZeneca's Hypertension Drug Lowers Blood Pressure in 'Meaningful, Sustained' Manner - MarketScreener
Technical analysis overview for AstraZeneca PLC Depositary Receipt stock2025 Volume Leaders & Technical Confirmation Trade Alerts - Newser
Shareholders that lost money on AstraZeneca PLC (AZN) should contact Levi & Korsinsky about pending Class ActionAZN - ACCESS Newswire
AstraZeneca to seek approval for antihypertensive this year (AZN) - Seeking Alpha
AstraZeneca Faces Close Race With Mineralys After Phase III Hypertension Readout - insights.citeline.com
15.7mmHg Blood Pressure Reduction: AstraZeneca's Novel Drug Shows Breakthrough in Treatment-Resistant HTN - Stock Titan
AstraZeneca to seek approval for blood pressure drug by year-end - MarketScreener
AstraZeneca PLC Depositary Receipt Included in Top Momentum ScanJuly 2025 Update & Technical Pattern Based Signals - beatles.ru
What does recent volatility data suggest for AstraZeneca PLC Depositary Receipt2025 Trade Ideas & Technical Buy Zone Confirmations - Newser
Using Ichimoku Cloud for AstraZeneca PLC Depositary Receipt technicalsWeekly Trade Summary & Free AI Powered Buy and Sell Recommendations - Newser
Is it time to cut losses on AstraZeneca PLC Depositary ReceiptWeekly Trade Report & Safe Capital Growth Plans - Newser
SGLT2 Inhibitors Market to Hit USD 29.73 Billion by 2032, Driven by Expanding Diabetes Management and Cardiovascular Benefits – SNS Insider - GlobeNewswire Inc.
AstraZeneca PLC (AZN) Oncology Sales Hit $12B in H1 2025 - MSN
AstraZeneca Challenges Colo. Law Over Drug Pricing Rules - Law360
Characterization of Astrazeneca’s AZD-0233 for cardiovascular disease - BioWorld MedTech
Gout Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review | AstraZeneca, R-Pharm, Allena Pharma, JW Pharma, Hinova pharma, Jiangsu Hengrui Medicine, Selecta Biosciences, LG Chem - Barchart.com
Is a relief rally coming for AstraZeneca PLC Depositary Receipt holdersRate Cut & Real-Time Volume Analysis - Newser
Applying chart zones and confluence areas to AstraZeneca PLC Depositary ReceiptJuly 2025 Analyst Calls & Free Daily Entry Point Trade Alerts - Newser
Evaluating AstraZeneca PLC Depositary Receipt with trendline analysisJuly 2025 Pullbacks & Short-Term Swing Trade Alerts - Newser
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):